These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 24131304

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
    Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, Bradding P, Gauvreau GM, Sumino K, FitzGerald JM, Israel E, Bjermer L, Bourdin A, Arron JR, Choy DF, Olsson JK, Abreu F, Howard M, Wong K, Cai F, Peng K, Putnam WS, Holweg CTJ, Matthews JG, Kraft M, Woodruff PG, CLAVIER Investigators.
    Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. OX40L blockade and allergen-induced airway responses in subjects with mild asthma.
    Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M, Kipling C, Dua B, Mosesova S, Putnam W, Zheng Y, Scheerens H, McClintock D, Matthews JG, O'Byrne PM.
    Clin Exp Allergy; 2014 Jan; 44(1):29-37. PubMed ID: 24224471
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
    Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.
    Respir Med; 2018 Jan; 134():143-149. PubMed ID: 29413502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
    Liu Y, Zhang S, Chen R, Wei J, Guan G, Zhou M, Dong N, Cao Y.
    Allergy Asthma Proc; 2018 Sep 01; 39(5):332-337. PubMed ID: 30153886
    [Abstract] [Full Text] [Related]

  • 10. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
    Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.
    Thorax; 2015 Aug 01; 70(8):748-56. PubMed ID: 26001563
    [Abstract] [Full Text] [Related]

  • 11. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.
    Leaker BR, Barnes PJ, O'Connor BJ, Ali FY, Tam P, Neville J, Mackenzie LF, MacRury T.
    Clin Exp Allergy; 2014 Sep 01; 44(9):1146-53. PubMed ID: 25040039
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
    Diamant Z, Sidharta PN, Singh D, O'Connor BJ, Zuiker R, Leaker BR, Silkey M, Dingemanse J.
    Clin Exp Allergy; 2014 Aug 01; 44(8):1044-52. PubMed ID: 24964348
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lebrikizumab in the personalized management of asthma.
    Thomson NC, Patel M, Smith AD.
    Biologics; 2012 Aug 01; 6():329-35. PubMed ID: 23055690
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
    Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.
    N Engl J Med; 2015 May 21; 372(21):1987-95. PubMed ID: 25981191
    [Abstract] [Full Text] [Related]

  • 20. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
    Zhu R, Zheng Y, Dirks NL, Vadhavkar S, Jin JY, Peng K, Holweg CTJ, Olsson J, Matthews JG, Putnam WS.
    Pulm Pharmacol Ther; 2017 Oct 21; 46():88-98. PubMed ID: 28843617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.